J&J to acquire medtech company for $16.6B

Johnson & Johnson will acquire Abiomed, a medtech company based in Danvers, Mass., for $16.6 billion by the end of the first quarter of 2023. 

Advertisement

Abiomed, which specializes in cardiovascular devices, will work as a standalone business as part of J&J’s MedTech operations, according to a Nov. 1 J&J news release. 

Both boards of directors approved the acquisition, which J&J said would expand its portfolio of heart failure devices.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.